Lu Yong-Kun, Yang Hai-Yan, Liu Xiang-Zhe, Wang Yan-Hua, Yang Jun-Hong
the First Ward of Cerebral Disease,the First Affiliated Hospital of Henan University of Chinese Medicine Zhengzhou 450000,China.
Zhongguo Zhong Yao Za Zhi. 2019 Apr;44(8):1696-1703. doi: 10.19540/j.cnki.cjcmm.20181204.012.
To study the effect of modified Buyang Huanwu Decoction on the hemorrhagic transformation after intravenous thrombolysis of recombinant tissue type plasminogen activator(rt-PA) in patients with super early(onset time<4. 5 h) cerebral infarction. From March 2016 to July 2018,at the brain disease zone of the First Affiliated Hospital of Henan University of Traditional Chinese Medicine,212 cases of super early cerebral infarction were selected and divided into two group according to the randomized complete blocks designs: control group(106 cases) and traditional Chinese medicine group(106 cases). The control group was treated with rt-PA intravenous thrombolysis,while the traditional Chinese medicine group was treated with modified Buyang Huanwu Decoction in addition to the therapy of the control group. Both groups were treated for 14 days. Neurological deficit score,serum matrix metalloproteinase-9(MMP-9),neuron specific enolase(NSE),vascular endothelial growth factor(VEGF) and plasma cellular fibronectin(c-FN) levels,the incidence of hemorrhagic transformation,clinical efficacy and adverse drug reactions before and after treatment were compared between the two groups. According to the findings,at the 14 thday after treatment,the rank sum test of the grade data showed that the clinical efficacy of the traditional Chinese medicine group was better than that of the control group(Z =-2. 033,P = 0. 042); on the basis of χ2 test,the total efficiency of the traditional Chinese medicine group was higher than that of the control group(χ2= 4. 895,P =0. 027); the hemorrhagic transformation rate of the traditional Chinese medicine group was lower than that of the control group within14 days of treatment(χ2= 3. 962,P = 0. 047). MMP-9 levels in the traditional Chinese medicine group were lower than those in the control group at the 3 rd,5 th,7 th,10 th,14 thd after treatment(t =-2. 474,-3. 022,-5. 163,-6. 998,-9. 821; P = 0. 014,0. 003,0,0,0). The improvement of c-FN,NSE,VEGF and NIHSS scores in the traditional Chinese medicine group was superior to that of the control group after 14 days of treatment(t =-2. 343,-3. 187,-2. 129,-3. 105; P = 0. 020,0. 002,0. 034,0. 002). No obvious adverse reactions of modified Buyang Huanwu Decoction were observed during 14 days of treatment. Modified Buyang Huanwu Decoction could reduce the expressions of MMP-9,c-FN,NSE and VEGF after rt-PA intravenous thrombolysis in patients with super early cerebral infarction,and decrease the hemorrhagic transformation rate after thrombolysis,with high safety.
观察补阳还五汤加减对超早期(发病时间<4.5小时)脑梗死患者重组组织型纤溶酶原激活剂(rt-PA)静脉溶栓后出血转化的影响。选取2016年3月至2018年7月河南中医药大学第一附属医院脑病科收治的超早期脑梗死患者212例,按照随机区组设计分为对照组(106例)和中药组(106例)。对照组采用rt-PA静脉溶栓治疗,中药组在对照组治疗基础上加用补阳还五汤加减治疗。两组均治疗14天。比较两组治疗前后神经功能缺损评分、血清基质金属蛋白酶-9(MMP-9)、神经元特异性烯醇化酶(NSE)、血管内皮生长因子(VEGF)及血浆细胞纤维连接蛋白(c-FN)水平、出血转化发生率、临床疗效及药物不良反应。结果显示,治疗第14天,等级资料秩和检验结果显示中药组临床疗效优于对照组(Z=-2.033,P=0.042);基于χ2检验,中药组总有效率高于对照组(χ2=4.895,P=0.027);治疗14天内中药组出血转化率低于对照组(χ2=3.962,P=0.047)。治疗后第3、5、7、10、14天中药组MMP-9水平低于对照组(t=-2.474、-3.022、-5.163、-6.998、-9.821;P=0.014、0.003、0、0、0)。治疗14天后中药组c-FN、NSE、VEGF及美国国立卫生研究院卒中量表(NIHSS)评分改善情况优于对照组(t=-2.343、-3.187、-2.129、-3.105;P=0.020、0.002、0.034、0.002)。治疗14天期间未观察到补阳还五汤加减明显的不良反应。补阳还五汤加减可降低超早期脑梗死患者rt-PA静脉溶栓后MMP-9、c-FN、NSE及VEGF的表达,降低溶栓后出血转化率,安全性高。